AVASTIN

This brand name is authorized in United States. It is also authorized in Austria, Brazil, Canada, Croatia, Cyprus, Ecuador, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Japan, Lithuania, Netherlands, New Zealand, Nigeria, Poland, Romania, Singapore, South Africa, Spain, Tunisia, UK.

Active ingredients

The drug AVASTIN contains one active pharmaceutical ingredient (API):

1	Bevacizumab UNII 2S9ZZM9Q9V - BEVACIZUMAB
	Bevacizumab binds to vascular endothelial growth factor (VEGF), the key driver of vasculogenesis and angiogenesis, and thereby inhibits the binding of VEGF to its receptors, Flt-1 (VEGFR-1) and KDR (VEGFR-2), on the surface of endothelial cells. Neutralising the biological activity of VEGF regresses the vascularisation of tumours, normalises remaining tumour vasculature, and inhibits the formation of new tumour vasculature, thereby inhibiting tumour growth.
	Read more about Bevacizumab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
AVASTIN Concentrate for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01FG01	Bevacizumab	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FG VEGF/VEGFR (Vascular Endothelial Growth Factor) inhibitors
Discover more medicines within L01FG01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	529207901139218, 529207902151211
CA	Health Products and Food Branch	02270994
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	28761-02-09
EE	Ravimiamet	1179952, 1187973
ES	Centro de información online de medicamentos de la AEMPS	04300001, 04300002
FI	Lääkealan turvallisuus- ja kehittämiskeskus	019445, 019781
FR	Base de données publique des médicaments	60391646
GB	Medicines & Healthcare Products Regulatory Agency	91527, 91530
HK	Department of Health Drug Office	56637, 56638, 59449, 59450
IL	מִשְׂרַד הַבְּרִיאוּת	4932, 4933
JP	医薬品医療機器総合機構	4291413A1022, 4291413A2029
LT	Valstybinė vaistų kontrolės tarnyba	1027602, 1027603
NG	Registered Drug Product Database	A6-0123
Switch country to Nigeria in order to find specific presentations of AVASTIN
NL	Z-Index G-Standaard	15023753
NL	Z-Index G-Standaard, PRK	76910, 76929
NZ	Medicines and Medical Devices Safety Authority	11531
PL	Rejestru Produktów Leczniczych	100129386
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W64373001, W64373002
SG	Health Sciences Authority	13065P, 14097P
TN	Direction de la Pharmacie et du Médicament	6993191H, 6993192H
US	FDA, National Drug Code	50242-060, 50242-061
ZA	Health Products Regulatory Authority	A39/26/0314, A39/26/0315